Cardiovascular treatment prior to hospitalisation was commonly used with heart failure drug treatment in 90% (any of ACE inhibitors, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter-2 inhibitors and beta blockers). This evidence concerns the gene NR3C2 and heart failure.